Therapeutic strategies for COVID-19: progress and lessons learned
G Li, R Hilgenfeld, R Whitley, E De Clercq - Nature Reviews Drug …, 2023 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
[HTML][HTML] Therapeutics for COVID-19 and post COVID-19 complications: An update
Since its inception in late December 2020 in China, novel coronavirus has affected the
global socio-economic aspect. Currently, the world is seeking safe and effective treatment …
global socio-economic aspect. Currently, the world is seeking safe and effective treatment …
Replication kinetics and infectivity of SARS-CoV-2 variants of concern in common cell culture models
L Mautner, M Hoyos, A Dangel, C Berger, A Ehrhardt… - Virology journal, 2022 - Springer
Abstract Background During the ongoing Covid-19 pandemic caused by the emerging virus
SARS-CoV-2, research in the field of coronaviruses has expanded tremendously. The …
SARS-CoV-2, research in the field of coronaviruses has expanded tremendously. The …
[HTML][HTML] Protein structure-based in-silico approaches to drug discovery: Guide to COVID-19 therapeutics
With more than 5 million fatalities and close to 300 million reported cases, COVID-19 is the
first documented pandemic due to a coronavirus that continues to be a major health …
first documented pandemic due to a coronavirus that continues to be a major health …
Potent anti-SARS-CoV-2 activity by the natural product gallinamide A and analogues via inhibition of cathepsin L
AS Ashhurst, AH Tang, P Fajtová… - Journal of medicinal …, 2021 - ACS Publications
Cathepsin L is a key host cysteine protease utilized by coronaviruses for cell entry and is a
promising drug target for novel antivirals against SARS-CoV-2. The marine natural product …
promising drug target for novel antivirals against SARS-CoV-2. The marine natural product …
Challenges for targeting SARS-CoV-2 proteases as a therapeutic strategy for COVID-19
Two proteases produced by the SARS-CoV-2 virus, the main protease and papain-like
protease, are essential for viral replication and have become the focus of drug development …
protease, are essential for viral replication and have become the focus of drug development …
Structure-based discovery of dual pathway inhibitors for SARS-CoV-2 entry
H Wang, Q Yang, X Liu, Z Xu, M Shao, D Li… - Nature …, 2023 - nature.com
Abstract Since 2019, SARS-CoV-2 has evolved rapidly and gained resistance to multiple
therapeutics targeting the virus. Development of host-directed antivirals offers broad …
therapeutics targeting the virus. Development of host-directed antivirals offers broad …
A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells
M Mahoney, VC Damalanka… - Proceedings of the …, 2021 - National Acad Sciences
The host cell serine protease TMPRSS2 is an attractive therapeutic target for COVID-19 drug
discovery. This protease activates the Spike protein of severe acute respiratory syndrome …
discovery. This protease activates the Spike protein of severe acute respiratory syndrome …
MPI8 is potent against SARS‐CoV‐2 by inhibiting dually and selectively the SARS‐CoV‐2 main protease and the host cathepsin L
A number of inhibitors have been developed for the SARS‐CoV‐2 main protease (MPro) as
potential COVID‐19 medications but little is known about their selectivity. Using enzymatic …
potential COVID‐19 medications but little is known about their selectivity. Using enzymatic …
Evaluation of SARS-CoV-2 main protease inhibitors using a novel cell-based assay
As an essential enzyme of SARS-CoV-2, main protease (MPro) triggers acute toxicity to its
human cell host, an effect that can be alleviated by an MPro inhibitor. Using this toxicity …
human cell host, an effect that can be alleviated by an MPro inhibitor. Using this toxicity …